Diabetes, Vol 39, Issue 6 752-756, Copyright © 1990 by American Diabetes Association

ARTICLES

Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans

PC Butler, J Chou, WB Carter, YN Wang, BH Bu, D Chang, JK Chang and RA Rizza
Department of Medicine, Mayo Medical School, Rochester, Minnesota 55905.

Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in approximately 50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro. Immunocytochemical studies have colocalized amylin and insulin within beta-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P less than 0.001) in the plasma concentration of amylin (from 2.03 +/- 0.22 to 3.78 +/- 0.39 pM) and insulin (from 48.3 +/- 3.1 to 265 +/- 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P less than 0.001) and the increase in insulin and amylin concentration (r = 0.65, P less than 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Bonner-Weir and T. D. O'Brien Islets in Type 2 Diabetes: In Honor of Dr. Robert C. Turner Diabetes, November 1, 2008; 57(11): 2899 - 2904. [Full Text] [PDF]

				C.-Y. Lin, T. Gurlo, R. Kayed, A. E. Butler, L. Haataja, C. G. Glabe, and P. C. Butler Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP-Induced {beta}-Cell Apoptosis in h-IAPP Transgenic Mice Diabetes, May 1, 2007; 56(5): 1324 - 1332. [Abstract] [Full Text] [PDF]

				A. V. Matveyenko and P. C. Butler {beta}-Cell Deficit Due to Increased Apoptosis in the Human Islet Amyloid Polypeptide Transgenic (HIP) Rat Recapitulates the Metabolic Defects Present in Type 2 Diabetes. Diabetes, July 1, 2006; 55(7): 2106 - 2114. [Abstract] [Full Text] [PDF]

				K. J. Pulman, W. M. Fry, G. T. Cottrell, and A. V. Ferguson The Subfornical Organ: A Central Target for Circulating Feeding Signals J. Neurosci., February 15, 2006; 26(7): 2022 - 2030. [Abstract] [Full Text] [PDF]

				C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]

				I. R. Reid, A. Horne, B. Mason, R. Ames, U. Bava, and G. D. Gamble Effects of Calcium Supplementation on Body Weight and Blood Pressure in Normal Older Women: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3824 - 3829. [Abstract] [Full Text] [PDF]

				J. F. Paulsson and G. T. Westermark Aberrant Processing of Human Proislet Amyloid Polypeptide Results in Increased Amyloid Formation Diabetes, July 1, 2005; 54(7): 2117 - 2125. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Jang, T. Gurlo, M. D. Carty, W. C. Soeller, and P. C. Butler Diabetes Due to a Progressive Defect in {beta}-Cell Mass in Rats Transgenic for Human Islet Amyloid Polypeptide (HIP Rat): A New Model for Type 2 Diabetes Diabetes, June 1, 2004; 53(6): 1509 - 1516. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Janson, W. C. Soeller, and P. C. Butler Increased {beta}-Cell Apoptosis Prevents Adaptive Increase in {beta}-Cell Mass in Mouse Model of Type 2 Diabetes: Evidence for Role of Islet Amyloid Formation Rather Than Direct Action of Amyloid Diabetes, September 1, 2003; 52(9): 2304 - 2314. [Abstract] [Full Text] [PDF]

				R. A. Ritzel and P. C. Butler Replication Increases {beta}-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis Diabetes, July 1, 2003; 52(7): 1701 - 1708. [Abstract] [Full Text] [PDF]

				T. A. Buchanan, A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. N. Hodis, et al. Preservation of Pancreatic {beta}-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women Diabetes, September 1, 2002; 51(9): 2796 - 2803. [Abstract] [Full Text] [PDF]

				N. G. Knowles, M. A. Landchild, W. Y. Fujimoto, and S. E. Kahn Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes Diabetes Care, February 1, 2002; 25(2): 292 - 297. [Abstract] [Full Text] [PDF]

				T. A. Lutz, S. Tschudy, A. Mollet, N. Geary, and E. Scharrer Dopamine D2 receptors mediate amylin's acute satiety effect Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2001; 280(6): R1697 - R1703. [Abstract] [Full Text] [PDF]

				M. Hoenig, G. Hall, D. Ferguson, K. Jordan, M. Henson, K. Johnson, and T. O'Brien A Feline Model of Experimentally Induced Islet Amyloidosis Am. J. Pathol., December 1, 2000; 157(6): 2143 - 2150. [Abstract] [Full Text] [PDF]

				S. Mäkimattila, M. S. Fineman, and H. Yki-Järvinen Deficiency of Total and Nonglycosylated Amylin in Plasma Characterizes Subjects with Impaired Glucose Tolerance and Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2822 - 2827. [Abstract] [Full Text]

				F. Wang, T. E. Adrian, G. T. Westermark, X. Ding, T. Gasslander, and J. Permert Islet amyloid polypeptide tonally inhibits beta -, alpha -, and delta -cell secretion in isolated rat pancreatic islets Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E19 - E24. [Abstract] [Full Text] [PDF]

				C. J. Dechenes, C. B. Verchere, S. Andrikopoulos, and S. E. Kahn Human aging is associated with parallel reductions in insulin and amylin release Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E785 - E791. [Abstract] [Full Text] [PDF]

				U. Arnelo, R. Reidelberger, T. E. Adrian, J. Larsson, and J. Permert Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1998; 275(5): R1537 - R1542. [Abstract] [Full Text] [PDF]

				J. L. Leahy and M. S. Fineman Impaired phasic insulin and amylin secretion in diabetic rats Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E457 - E462. [Abstract] [Full Text] [PDF]

				T. A. Lutz, J. Althaus, R. Rossi, and E. Scharrer Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1998; 274(6): R1777 - R1782. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, and J. L. Ivy Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E6 - E12. [Abstract] [Full Text] [PDF]

				U. Arnelo, J. Permert, J. Larsson, R. D. Reidelberger, C. Arnelo, and T. E. Adrian Chronic Low Dose Islet Amyloid Polypeptide Infusion Reduces Food Intake, But Does Not Influence Glucose Metabolism, in Unrestrained Conscious Rats: Studies Using a Novel Aortic Catheterization Technique Endocrinology, October 1, 1997; 138(10): 4081 - 4085. [Abstract] [Full Text] [PDF]

				J. Permert, J. Larsson, G. T. Westermark, M. K. Herrington, L. Christmanson, P. M. Pour, P. Westermark, and T. E. Adrian Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes N. Engl. J. Med., February 3, 1994; 330(5): 313 - 318. [Abstract] [Full Text]

				W. M. Macfarlane, S. C. Campbell, L. J. Elrick, V. Oates, G. Bermano, K. J. Lindley, A. Aynsley-Green, M. J. Dunne, R. F. L. James, and K. Docherty Glucose Regulates Islet Amyloid Polypeptide Gene Transcription in a PDX1- and Calcium-dependent Manner J. Biol. Chem., May 12, 2000; 275(20): 15330 - 15335. [Abstract] [Full Text] [PDF]